Risk Factors of Cardiovascular Diseases in HIV/AIDS Patients on HAART.
Risk Factors of Cardiovascular Diseases in HIV/AIDS Patients on HAART.
复制标题
DOI：
10.2174/1874613601509010051
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Ngowe MN
中科院分区：
文献类型：
--
作者：
Nsagha DS;Assob JC;Njunda AL;Tanue EA;Kibu OD;Ayima CW;Ngowe MN
在20世纪90年代中期，被称为高效抗逆转录病毒疗法（HAART）的组合抗逆转录病毒疗法的引入和广泛使用已经导致HIV感染个体经历免疫缺陷相关事件和死亡的急剧下降。人们越来越关注与HIV和HAART相关的代谢并发症，这可能会增加心血管风险和疾病。本研究的目的是调查在喀麦隆西南地区的艾滋病毒/艾滋病治疗中心接受HAART和未接受HAART的艾滋病毒/艾滋病患者的心血管风险状况。 将接受HAART治疗的受试者与HAART初治受试者进行比较。问卷调查管理，人体测量和血压测量记录在标准条件下。采集血样，测定血糖和血脂水平。 招募了215名参与者，160名（74.4%）接受HAART治疗，55名（25.6%）未接受HAART治疗。在个体血脂异常中，总胆固醇升高最常见（40.0%）。与HAART经验不足组相比，HAART参与者发生高胆固醇血症的风险显著约为8倍（OR 8.17; 95% CI：3.31-20.14; p<0.001）。高血压的患病率为25.6%（95% CI：15.3%-35.9%），HAART治疗组的高血压患病率是HAART未治疗组的2倍（p=0.033）。与女性（11.2%）相比，男性（24.1%）的低HDL-c患病率显著更高（p=0.0196）。与男性（7.4%）相比，许多女性（27.3%）肥胖（p=0.0043）。HAART使用和治疗持续时间超过5年与CVD危险因素的患病率较高显著相关。 HAART治疗与高胆固醇血症、LDL-c升高和高血压的患病率显著升高相关，因此与心血管疾病的风险相关。
The introduction and widespread use of combination antiretroviral therapy referred to as highly active antiretroviral therapy (HAART) in the mid 1990’s, has led HIV-infected individuals to experience a dramatic decline in immunodeficiency-related events and death. There is growing concern on metabolic complications associated with HIV and HAART which may increase cardiovascular risk and disease. The aim of this study was to investigate the cardiovascular risk profile of HIV/AIDS patients receiving HAART and those not receiving HAART at HIV/AIDS treatment centres in the South West Region of Cameroon. Consenting participants, who had been receiving HAART, were compared with HAART naive participants. A questionnaire was administered; anthropometric and blood pressure measurements were recorded under standard conditions. Blood samples were obtained for the determination of plasma glucose and lipid levels. Two hundred and fifteen participants were recruited, 160 (74.4%) were on HAART and 55 (25.6%) were HAART naive. Among the individual lipid abnormalities, increased total cholesterol was the most prevalent (40.0%). Participants on HAART were significantly about 8 times at risk of developing hypercholesterolemia when compared to the HAART inexperienced group (OR 8.17; 95% CI: 3.31-20.14; p<0.001). Hypertension had a prevalence of 25.6% (95% CI: 15.3%-35.9%) and was about 2 times significantly higher in the HAART treated than the HAART untreated group (p=0.033). The prevalence of low HDL-c was significantly higher in males (24.1%) compared to females (11.2%) (p=0.0196). Many females (27.3%) were obese compared to males (7.4%) (p=0.0043). HAART use and treatment duration of more than five years were significantly associated with higher prevalence of CVD risk factors. HAART treatment was associated with significantly higher prevalence of hypercholesterolemia, increased LDL-c and hypertension, hence the risk of cardiovascular diseases.